Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2022-03-07 02:51:45 UTC |
---|
HMDB ID | HMDB0014839 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Amprenavir |
---|
Description | Amprenavir, also known as agenerase or vertex VX478, belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring. Amprenavir is a drug which is used for the treatment of hiv-1 infection in combination with other antiretroviral agents. It was patented in 1992 and approved for medical use in 1999. Incorporation of an amino alcohol moiety proved crucial to inhibitory activity for many of these agents. Research aimed at development of renin inhibitors as potential antihypertensive agents had led to the discovery of compounds that blocked the action of this peptide cleaving enzyme. Amprenavir is a moderately basic compound (based on its pKa). Amprenavir is a potentially toxic compound. Structure–activity studies on renin inhibitors proved to be of great value for developing HIV protease inhibitors. Amprenavir (original brand name Agenerase, GlaxoSmithKline) is a protease inhibitor used to treat HIV infection. The convenient dosing came at a price, as the dose required is 1,200 mg, delivered in 8 (eight) very large 150 mg gel capsules or 24 (twenty-four) 50 mg gel capsules twice daily. This unit is closely related to the one found in the statine, an unusual amino acid that forms part of the pepstatin, a fermentation product that inhibits protease enzymes. The amino acid sequence cleaved by renin was found to be fortuitously the same as that required to produce the HIV peptide coat. Production of amprenavir was discontinued by the manufacturer on December 31, 2004; a prodrug version (fosamprenavir), is available. It was approved by the Food and Drug Administration on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours. |
---|
Structure | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1 |
---|
Synonyms | Value | Source |
---|
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate | ChEBI | Agenerase | ChEBI | (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamic acid | Generator | (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulphonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate | Generator | (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulphonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamic acid | Generator | AMP | HMDB | AMV | HMDB | VX-478 | HMDB | GlaxoSmithKline brand OF amprenavir | HMDB | Vertex VX478 | HMDB | Glaxo wellcome brand OF amprenavir | HMDB | Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate | HMDB |
|
---|
Chemical Formula | C25H35N3O6S |
---|
Average Molecular Weight | 505.627 |
---|
Monoisotopic Molecular Weight | 505.224656557 |
---|
IUPAC Name | (3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)4-aminobenzenesulfonamido]-1-phenylbutan-2-yl]carbamate |
---|
Traditional Name | amprenavir |
---|
CAS Registry Number | 161814-49-9 |
---|
SMILES | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 |
---|
InChI Identifier | InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1 |
---|
InChI Key | YMARZQAQMVYCKC-OEMFJLHTSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Benzenesulfonamides |
---|
Direct Parent | Aminobenzenesulfonamides |
---|
Alternative Parents | |
---|
Substituents | - Aminobenzenesulfonamide
- Phenylbutylamine
- Amphetamine or derivatives
- Benzenesulfonyl group
- Aniline or substituted anilines
- Organosulfonic acid amide
- Organic sulfonic acid or derivatives
- Organosulfonic acid or derivatives
- Aminosulfonyl compound
- Carbamic acid ester
- Tetrahydrofuran
- Sulfonyl
- Carbonic acid derivative
- Secondary alcohol
- Dialkyl ether
- Ether
- Oxacycle
- Organoheterocyclic compound
- Organic oxide
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Amine
- Alcohol
- Carbonyl group
- Primary amine
- Hydrocarbon derivative
- Organic nitrogen compound
- Organic oxygen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.049 g/L | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Amprenavir,1TMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 4047.3 | Semi standard non polar | 33892256 | Amprenavir,1TMS,isomer #2 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4181.4 | Semi standard non polar | 33892256 | Amprenavir,1TMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 3908.6 | Semi standard non polar | 33892256 | Amprenavir,2TMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4111.0 | Semi standard non polar | 33892256 | Amprenavir,2TMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 3651.9 | Standard non polar | 33892256 | Amprenavir,2TMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 5089.5 | Standard polar | 33892256 | Amprenavir,2TMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 3894.0 | Semi standard non polar | 33892256 | Amprenavir,2TMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 3656.5 | Standard non polar | 33892256 | Amprenavir,2TMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 5503.0 | Standard polar | 33892256 | Amprenavir,2TMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4017.1 | Semi standard non polar | 33892256 | Amprenavir,2TMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 3757.4 | Standard non polar | 33892256 | Amprenavir,2TMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 5178.3 | Standard polar | 33892256 | Amprenavir,2TMS,isomer #4 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4060.9 | Semi standard non polar | 33892256 | Amprenavir,2TMS,isomer #4 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 3751.0 | Standard non polar | 33892256 | Amprenavir,2TMS,isomer #4 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 5195.6 | Standard polar | 33892256 | Amprenavir,3TMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4017.5 | Semi standard non polar | 33892256 | Amprenavir,3TMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 3749.3 | Standard non polar | 33892256 | Amprenavir,3TMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4820.2 | Standard polar | 33892256 | Amprenavir,3TMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4036.8 | Semi standard non polar | 33892256 | Amprenavir,3TMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 3750.6 | Standard non polar | 33892256 | Amprenavir,3TMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4811.0 | Standard polar | 33892256 | Amprenavir,3TMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 3979.9 | Semi standard non polar | 33892256 | Amprenavir,3TMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 3847.8 | Standard non polar | 33892256 | Amprenavir,3TMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4898.6 | Standard polar | 33892256 | Amprenavir,4TMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4005.7 | Semi standard non polar | 33892256 | Amprenavir,4TMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 3857.5 | Standard non polar | 33892256 | Amprenavir,4TMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4556.8 | Standard polar | 33892256 | Amprenavir,1TBDMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 4272.9 | Semi standard non polar | 33892256 | Amprenavir,1TBDMS,isomer #2 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4402.6 | Semi standard non polar | 33892256 | Amprenavir,1TBDMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4172.2 | Semi standard non polar | 33892256 | Amprenavir,2TBDMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4555.0 | Semi standard non polar | 33892256 | Amprenavir,2TBDMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4109.5 | Standard non polar | 33892256 | Amprenavir,2TBDMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 5130.2 | Standard polar | 33892256 | Amprenavir,2TBDMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4369.0 | Semi standard non polar | 33892256 | Amprenavir,2TBDMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4123.9 | Standard non polar | 33892256 | Amprenavir,2TBDMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 5462.0 | Standard polar | 33892256 | Amprenavir,2TBDMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4479.4 | Semi standard non polar | 33892256 | Amprenavir,2TBDMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4211.1 | Standard non polar | 33892256 | Amprenavir,2TBDMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 5191.4 | Standard polar | 33892256 | Amprenavir,2TBDMS,isomer #4 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 4494.1 | Semi standard non polar | 33892256 | Amprenavir,2TBDMS,isomer #4 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 4199.2 | Standard non polar | 33892256 | Amprenavir,2TBDMS,isomer #4 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 5175.1 | Standard polar | 33892256 | Amprenavir,3TBDMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4684.9 | Semi standard non polar | 33892256 | Amprenavir,3TBDMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4411.7 | Standard non polar | 33892256 | Amprenavir,3TBDMS,isomer #1 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4897.5 | Standard polar | 33892256 | Amprenavir,3TBDMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 4660.1 | Semi standard non polar | 33892256 | Amprenavir,3TBDMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 4393.6 | Standard non polar | 33892256 | Amprenavir,3TBDMS,isomer #2 | CC(C)CN(C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 4851.2 | Standard polar | 33892256 | Amprenavir,3TBDMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 4614.3 | Semi standard non polar | 33892256 | Amprenavir,3TBDMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 4497.6 | Standard non polar | 33892256 | Amprenavir,3TBDMS,isomer #3 | CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 4925.8 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Amprenavir GC-MS (Non-derivatized) - 70eV, Positive | splash10-022d-8491400000-418cbb7f08471fa84619 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Amprenavir GC-MS (1 TMS) - 70eV, Positive | splash10-03kc-7192320000-fa264cdbd41779709c30 | 2017-10-06 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Amprenavir LC-ESI-qTof , Positive-QTOF | splash10-05mk-2692510000-696582f37a165753c2f5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 10V, Positive-QTOF | splash10-0a4r-9000500000-e60fa95c31e43c49b031 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 20V, Positive-QTOF | splash10-0a4i-9001100000-2c5d3283dd48ceae82dd | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 40V, Positive-QTOF | splash10-0a4i-9010000000-cd15933ef1ecd45d9b1c | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 10V, Negative-QTOF | splash10-0gbi-4304930000-6cf1884fae8acb8332ab | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 20V, Negative-QTOF | splash10-0173-9432500000-a4d70ca4c7ac6bd2930d | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 40V, Negative-QTOF | splash10-052f-9825100000-b5b4efee0204074368f4 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 10V, Positive-QTOF | splash10-000i-0046920000-a443e441b8dc951bec99 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 20V, Positive-QTOF | splash10-0a4i-2922000000-15960e61915142ff5b1e | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 40V, Positive-QTOF | splash10-0006-9200000000-78c87a49bf59b5f6c014 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 10V, Negative-QTOF | splash10-0uxr-2302980000-1c2dbf56f0de2b3df597 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 20V, Negative-QTOF | splash10-0a4i-3911710000-48ad17f577dc556faafc | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Amprenavir 40V, Negative-QTOF | splash10-0a4i-7900200000-41ad730c9ba505f33793 | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|